Skip to content
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Gynecology

Does Fallopian Tube Removal Prevent Ovarian Cancer?

At a Glance

Yes, removing the fallopian tubes (salpingectomy) significantly lowers the risk of ovarian cancer because the most common, aggressive ovarian cancers actually begin in the tubes. This surgery is highly recommended for women already undergoing pelvic surgery or seeking permanent birth control.

Yes, removing the fallopian tubes—a procedure called a salpingectomy—significantly reduces the risk of developing ovarian cancer [1][2]. Over the last two decades, medical research has fundamentally shifted our understanding of this disease, revealing that the most common and aggressive type of “ovarian” cancer actually begins in the fallopian tubes, not the ovaries themselves [3][4].

Because there is currently no reliable routine screening test for ovarian cancer (like a mammogram for breast cancer or a Pap smear for cervical cancer), preventing the disease from starting is a critical priority in gynecologic care [5]. Removing the fallopian tubes has become a frontline strategy for achieving this.

How this applies to you depends on your personal risk factors and whether you are already planning to have gynecologic surgery.

The “Tubal Origin” of Ovarian Cancer

For a long time, doctors believed that ovarian cancer started on the surface of the ovary. However, researchers discovered that most cases of high-grade serous ovarian carcinoma (the most common and deadly type of ovarian cancer) actually begin as abnormal cells at the fringed ends of the fallopian tubes, called the fimbriae [6][4].

These precancerous clusters of cells are known as Serous Tubal Intraepithelial Carcinoma (STIC) [4]. The process of normal cells turning into STIC and eventually into invasive cancer can take many years [7]. By removing the fallopian tubes before these cells have a chance to spread to the ovaries or the lining of the abdomen (peritoneum), the risk of cancer drops dramatically [1][2].

For Average-Risk Women: Opportunistic Salpingectomy

If you are at average risk for ovarian cancer and are already planning to have pelvic surgery—such as a hysterectomy or permanent birth control (sterilization)—medical guidelines now recommend removing the fallopian tubes at the same time [8][9]. This practice is called opportunistic salpingectomy, which simply means taking the opportunity to remove the tubes while already performing surgery [10].

  • Better than “getting your tubes tied”: In the past, women seeking permanent birth control would have their tubes clipped or burned (tubal ligation). Today, removing the entire tube (salpingectomy) is preferred because it offers much better protection against ovarian cancer while being just as effective for birth control [11][12].
  • No forced menopause: The ovaries, not the fallopian tubes, produce your reproductive hormones. Removing only the fallopian tubes does not cause early menopause or significantly affect your hormone levels [13][14].
  • Minimally invasive with standard risks: When done as a standalone procedure for permanent birth control, a salpingectomy is typically performed as a minimally invasive (laparoscopic) surgery using small incisions in the abdomen, with a recovery time of a few days to a week. Like all surgeries, it carries standard risks such as bleeding, infection, or reactions to anesthesia. However, studies show that removing the tubes during another surgery (like a C-section or hysterectomy) is very safe and does not significantly increase the risk of surgical complications or recovery time [9][15].

For the procedure to be fully protective, the surgeon must be careful to remove the entire tube, especially the fimbriae, because any leftover tubal tissue can still develop into cancer [16].

For High-Risk Women (e.g., BRCA Mutations)

If you have a genetic mutation that puts you at high risk for ovarian cancer—such as a BRCA1, BRCA2, RAD51C, RAD51D, or BRIP1 mutation, or if you have Lynch syndrome—the standard recommendation is different.

Because of the extremely high risk, medical guidelines recommend Risk-Reducing Salpingo-Oophorectomy (RRSO), which is the removal of both the fallopian tubes and the ovaries [17][18]. The exact recommended age depends on the specific mutation (for example, often 35–40 for BRCA1 carriers, and 40–45 for BRCA2 carriers), ideally once childbearing is complete [17].

Removing the ovaries will immediately trigger surgical menopause, which can cause symptoms like hot flashes, sexual dysfunction, and bone density loss [18]. Because of these side effects, researchers are studying an alternative two-step approach:

  1. Removing only the fallopian tubes first (to reduce cancer risk while keeping hormones). Note that even though the ovaries remain, removing the tubes permanently eliminates the ability to conceive naturally; you would require in-vitro fertilization (IVF) to have biological children.
  2. Removing the ovaries later, closer to the age of natural menopause.

This two-step process is called salpingectomy with delayed oophorectomy. However, this approach is currently experimental and is only recommended for high-risk women participating in clinical trials, because doctors do not yet know if it provides the exact same level of cancer protection as removing everything at once [14][19].

Common questions in this guide

Does removing fallopian tubes cause early menopause?
No, removing only your fallopian tubes does not cause early menopause or significantly change your hormone levels. Your reproductive hormones are produced by your ovaries, which are left in place during a standard salpingectomy.
Why is fallopian tube removal better than getting my tubes tied?
Removing the entire fallopian tube provides much better protection against ovarian cancer while being just as effective for permanent birth control. Traditional tubal ligation, where tubes are just clipped or burned, leaves tissue behind and does not offer the same level of cancer prevention.
What is an opportunistic salpingectomy?
An opportunistic salpingectomy is when a surgeon removes your fallopian tubes during a pelvic surgery you are already having, such as a C-section or hysterectomy. This conveniently lowers your risk of ovarian cancer without requiring a separate, standalone operation.
Where does ovarian cancer usually start?
Medical research shows that the most common and aggressive form of ovarian cancer actually begins as abnormal cells at the fringed ends of the fallopian tubes. These precancerous cells can eventually spread to the ovaries or the lining of the abdomen over many years.
What surgery is recommended for women with BRCA mutations?
Women with a high-risk genetic mutation, like BRCA1 or BRCA2, are generally advised to undergo a risk-reducing salpingo-oophorectomy. This surgery involves removing both the fallopian tubes and the ovaries to provide the highest level of protection against ovarian cancer.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.If I am already scheduled for a pelvic surgery (like a hysterectomy or C-section), am I a good candidate for an opportunistic salpingectomy?
  2. 2.How experienced are you with performing a complete salpingectomy, specifically ensuring no fimbrial tissue is left behind on the ovary?
  3. 3.What are the specific surgical risks and expected recovery times for me based on my personal health history?
  4. 4.(If high risk) Am I a candidate for clinical trials investigating delayed oophorectomy, or is immediate removal of both my ovaries and fallopian tubes recommended for my specific genetic mutation?
  5. 5.(If getting tubes tied) What are the pros and cons for me personally of having my entire tubes removed versus having a traditional tubal ligation?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Outcomes From Opportunistic Salpingectomy for Ovarian Cancer Prevention.

    Hanley GE, Pearce CL, Talhouk A, et al.

    JAMA network open 2022; (5(2)):e2147343 doi:10.1001/jamanetworkopen.2021.47343.

    PMID: 35138400
  2. 2

    Primary prevention of ovarian cancer by salpingectomy: that's one small step for a surgeon, one giant leap for patients.

    Runnebaum IB, Kather A

    Journal of cancer research and clinical oncology 2023; (149(10)):6799-6801 doi:10.1007/s00432-023-04697-z.

    PMID: 36991197
  3. 3

    Ovarian cancer.

    Matulonis UA, Sood AK, Fallowfield L, et al.

    Nature reviews. Disease primers 2016; (2()):16061 doi:10.1038/nrdp.2016.61.

    PMID: 27558151
  4. 4

    Proteomic analysis of PAX8 alterations provides new insights into its role as a master regulator of migration in high-grade serous ovarian cancer.

    Gamberi T

    Annals of translational medicine 2019; (7(Suppl 8)):S303 doi:10.21037/atm.2019.10.100.

    PMID: 32016022
  5. 5

    Completeness of salpingectomy intended for ovarian cancer risk reduction.

    Wong JWH, Killeen JL, Carney ME

    Gynecologic oncology 2019; (155(2)):280-282 doi:10.1016/j.ygyno.2019.09.005.

    PMID: 31522838
  6. 6

    Progress in the pathological arena of gynecological cancers.

    McCluggage WG

    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 2021; (155 Suppl 1()):107-114 doi:10.1002/ijgo.13871.

    PMID: 34669206
  7. 7

    Natural history of ovarian high-grade serous carcinoma from time effects of ovulation inhibition and progesterone clearance of p53-defective lesions.

    Wu NY, Fang C, Huang HS, et al.

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2020; (33(1)):29-37 doi:10.1038/s41379-019-0370-1.

    PMID: 31558785
  8. 8

    Prophylactic Salpingectomy during Hysterectomy for Benign Disease: A Prospective Study to Evaluate High-Grade Serous Ovarian Carcinoma Precursors.

    Tchartchian G, Bojahr B, Heils L, et al.

    Journal of clinical medicine 2022; (12(1)) doi:10.3390/jcm12010296.

    PMID: 36615096
  9. 9

    Opportunistic salpingectomy during gynecologic and non-gynecologic abdominopelvic procedures for ovarian cancer primary prevention: a cost-effectiveness analysis.

    Adjei NN, Yeh PG, Haas A, et al.

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2026; (36(6)):102884 doi:10.1016/j.ijgc.2025.102884.

    PMID: 41605705
  10. 10

    The fallopian tube as origin of ovarian cancer: Change of diagnostic and preventive strategies.

    Kyo S, Ishikawa N, Nakamura K, Nakayama K

    Cancer medicine 2020; (9(2)):421-431 doi:10.1002/cam4.2725.

    PMID: 31769234
  11. 11

    Association between pelvic inflammatory disease and subsequent salpingectomy on the risk for ovarian cancer.

    Falconer H, Yin L, Salehi S, Altman D

    European journal of cancer (Oxford, England : 1990) 2021; (145()):38-43 doi:10.1016/j.ejca.2020.11.046.

    PMID: 33418235
  12. 12

    Salpingectomy vs tubal ligation for sterilization: a systematic review and meta-analysis.

    Mills K, Marchand G, Sainz K, et al.

    American journal of obstetrics and gynecology 2021; (224(3)):258-265.e4 doi:10.1016/j.ajog.2020.09.011.

    PMID: 32941790
  13. 13

    The Impact of Opportunistic Salpingectomy on Ovarian Reserve: A Systematic Review.

    Radu T, Mar M, Tudorache V, Marginean C

    Journal of clinical medicine 2024; (13(11)) doi:10.3390/jcm13113296.

    PMID: 38893008
  14. 14

    Screening and prevention of ovarian cancer.

    Sideris M, Menon U, Manchanda R

    The Medical journal of Australia 2024; (220(5)):264-274 doi:10.5694/mja2.52227.

    PMID: 38353066
  15. 15

    Impact of opportunistic salpingectomy on anti-Müllerian hormone in patients undergoing laparoscopic hysterectomy: a multicentre randomised controlled trial.

    Song T, Kim MK, Kim ML, et al.

    BJOG : an international journal of obstetrics and gynaecology 2017; (124(2)):314-320 doi:10.1111/1471-0528.14182.

    PMID: 27342222
  16. 16

    Uncloaking the Fimbria Ovarica: Histologic Recognition of an Elusive Anatomic Structure.

    Seidman JD, Stone R, Moragianni VA, et al.

    The American journal of surgical pathology 2025; (49(10)):1042-1059 doi:10.1097/PAS.0000000000002414.

    PMID: 40338147
  17. 17

    Salpingectomy for the Risk Reduction of Ovarian Cancer: Is It Time for a Salpingectomy-alone Approach?

    Boerner T, Long Roche K

    Journal of minimally invasive gynecology 2021; (28(3)):403-408 doi:10.1016/j.jmig.2020.09.020.

    PMID: 33038519
  18. 18

    No. 366-Gynaecologic Management of Hereditary Breast and Ovarian Cancer.

    Jacobson M, Bernardini M, Sobel ML, et al.

    Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC 2018; (40(11)):1497-1510 doi:10.1016/j.jogc.2018.05.046.

    PMID: 30473125
  19. 19

    Postoperative Management After Risk-Reducing Salpingo-Oophorectomy for Hereditary Breast and Ovarian Cancer Syndrome: A Narrative Review on Balancing Oncologic Benefit and Quality of Life.

    Ishida H, Takashima A

    Cureus 2026; (18(1)):e101823 doi:10.7759/cureus.101823.

    PMID: 41717173

This page is for informational purposes only and does not replace professional medical advice. Always consult your gynecologist or oncologist about your personal risk factors, genetic profile, and surgical options.

Get notified when new evidence is published on Ovarian Cancer.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.